113 related articles for article (PubMed ID: 21536812)
21. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening.
Berry DP; Clarke P; Hardcastle JD; Vellacott KD
Br J Surg; 1997 Sep; 84(9):1274-6. PubMed ID: 9313712
[TBL] [Abstract][Full Text] [Related]
23. French colorectal cancer screening pilot programme: results of the first round.
Goulard H; Boussac-Zarebska M; Ancelle-Park R; Bloch J
J Med Screen; 2008; 15(3):143-8. PubMed ID: 18927097
[TBL] [Abstract][Full Text] [Related]
24. Recommendations on population screening for colorectal cancer in New Zealand. Members of the National Health Committee Working Party on Population Screening for Colorectal Cancer.
N Z Med J; 1999 Jan; 112(1080):4-6. PubMed ID: 10073156
[TBL] [Abstract][Full Text] [Related]
25. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.
Greenberg PD; Bertario L; Gnauck R; Kronborg O; Hardcastle JD; Epstein MS; Sadowski D; Sudduth R; Zuckerman GR; Rockey DC
Am J Gastroenterol; 2000 May; 95(5):1331-8. PubMed ID: 10811348
[TBL] [Abstract][Full Text] [Related]
26. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
[TBL] [Abstract][Full Text] [Related]
27. Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study.
Hoepffner N; Shastri YM; Hanisch E; Rösch W; Mössner J; Caspary WF; Stein J
Aliment Pharmacol Ther; 2006 Jan; 23(1):145-54. PubMed ID: 16393292
[TBL] [Abstract][Full Text] [Related]
28. High yield of colorectal neoplasia detected by colonoscopy following a positive faecal occult blood test in the NHS Bowel Cancer Screening Programme.
Lee TJ; Clifford GM; Rajasekhar P; Rutter MD; Kometa S; Ritchie MC; Waddup G; Nylander D; McNally RJ; Rees CJ
J Med Screen; 2011; 18(2):82-6. PubMed ID: 21852700
[TBL] [Abstract][Full Text] [Related]
29. Fecal occult blood testing: clinical value and limitations.
Simon JB
Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
[TBL] [Abstract][Full Text] [Related]
30. A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test.
Levi Z; Hazazi R; Rozen P; Vilkin A; Waked A; Niv Y
Aliment Pharmacol Ther; 2006 May; 23(9):1359-64. PubMed ID: 16629942
[TBL] [Abstract][Full Text] [Related]
31. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Smith A; Young GP; Cole SR; Bampton P
Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
[TBL] [Abstract][Full Text] [Related]
32. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.
Levin B; Hess K; Johnson C
Arch Intern Med; 1997 May; 157(9):970-6. PubMed ID: 9140267
[TBL] [Abstract][Full Text] [Related]
33. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
Clarke P; Jack F; Carey FA; Steele RJ
Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
[TBL] [Abstract][Full Text] [Related]
34. Screening for colorectal cancer.
Hakama M; Hoff G; Kronborg O; Påhlman L
Acta Oncol; 2005; 44(5):425-39. PubMed ID: 16118076
[TBL] [Abstract][Full Text] [Related]
35. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
36. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
[TBL] [Abstract][Full Text] [Related]
37. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.
Mandel JS; Bond JH; Church TR; Snover DC; Bradley GM; Schuman LM; Ederer F
N Engl J Med; 1993 May; 328(19):1365-71. PubMed ID: 8474513
[TBL] [Abstract][Full Text] [Related]
38. [Performance of the Hemoccult test in the screening of colorectal cancer and adenoma. Results of 5 screening campaigns in Saône-et-Loire].
Tazi MA; Faivre J; Lejeune C; Benhamiche AM; Dassonville F
Gastroenterol Clin Biol; 1999 May; 23(5):475-80. PubMed ID: 10429850
[TBL] [Abstract][Full Text] [Related]
39. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms.
Dancourt V; Lejeune C; Lepage C; Gailliard MC; Meny B; Faivre J
Eur J Cancer; 2008 Oct; 44(15):2254-8. PubMed ID: 18760592
[TBL] [Abstract][Full Text] [Related]
40. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
